Theodore B. Moore
YOU?
Author Swipe
View article: Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report
Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report Open
Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT a…
View article: Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation
Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation Open
Rationale Lung injury after hematopoietic stem cell transplantation (HCT) occurs due to infection, chemotherapy toxicity, and alloreactive inflammation. Analyses of bronchoalveolar lavage (BAL) fluid have revealed dominant pathobiologic si…
View article: Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant
Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant Open
Hematopoietic stem cell transplantation (HCT) is a potentially life-saving therapy but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulationWe previously showed that bronchoalveolar lavage (BAL) transc…
View article: Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and AKI following CAR-T cell infusion.
View article: Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S1. Nadir serum electrolyte concentrations grouped by patient ICANS status.
View article: Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S2. Trends in serum electrolyte concentrations following CAR T-cell infusion grouped by patient ICANS status.
View article: Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S4. Association of hypophosphatemia incidence by ICANS grade.
View article: Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S5. Associations between pre-infusion tumor burden and ICANS and hypophosphatemia.
View article: Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S8. Baseline and change in kidney function following CAR T therapy grouped by patient ICANS status.
View article: Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Range and interquartile range of nadir serum electrolyte values in patients with and without ICANS.
View article: Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Stratification of CRS, ICANS, and hypophosphatemia incidence rates by pre-emptive treatment with tocilizumab.
View article: Supplemental Figure Legends from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Figure Legends from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Supplemental Figure Legends
View article: Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S6. Histogram plots of nadir phosphorus values stratified by ICANS status.
View article: Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and ICANS in patients who developed CRS (n = 433).
View article: Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Neurological adverse events included within each neurological adverse event category for CAR T-cell recipients.
View article: Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S7. Coincidence of serum hypocalcemia with hypophosphatemia.
View article: Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S3. ICANS incidence and time to symptom onset.
View article: Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients.
View article: Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant
Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant Open
Hematopoietic stem cell transplantation (HCT) is potentially curative for numerous malignant and non-malignant diseases but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulation. Bronchoalveolar lavage…
View article: Prevalence of Viral Infections and Serious Complications in Pediatric Hematopoietic Stem Cell Transplant Patients: A Ten-Year Single-Institution Retrospective Study
Prevalence of Viral Infections and Serious Complications in Pediatric Hematopoietic Stem Cell Transplant Patients: A Ten-Year Single-Institution Retrospective Study Open
Post-transplant viral infection remains as a serious adverse event in pediatric patients, and thus prospective studies should be performed to implement early intervention and more aggressive treatment in select high-risk patients. More stu…
View article: Bone Marrow Failure Associated With Short Telomeres and Digenic Variants of Uncertain Significance in Telomere Biology Genes
Bone Marrow Failure Associated With Short Telomeres and Digenic Variants of Uncertain Significance in Telomere Biology Genes Open
Telomere Biology Disorders (TBD) are a group of heritable disorders characterized by short telomeres. We report two patients that presented with bone marrow failure (BMF), who were identified to have low telomere length (TL) and variants o…
View article: Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S2. Trends in serum electrolyte concentrations following CAR T-cell infusion grouped by patient ICANS status.
View article: Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Stratification of CRS, ICANS, and hypophosphatemia incidence rates by pre-emptive treatment with tocilizumab.
View article: Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
ICANS incidence and symptom duration in patients with various electrolyte derangements stratified by receipt of any repletion of the deficient electrolyte. ICANS incidence (top row, error bars represent 95% confidence interval (CI) in pati…
View article: Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S7. Coincidence of serum hypocalcemia with hypophosphatemia.
View article: Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S8. Baseline and change in kidney function following CAR T therapy grouped by patient ICANS status.
View article: Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S6. Histogram plots of nadir phosphorus values stratified by ICANS status.
View article: Figure 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of ICANS in patients stratified by the presence or absence of electrolyte derangements. Kaplan–Meier analyses comparing time to ICANS for patients stratified by the presence or absence of electrolyte derangements including (A) hy…
View article: Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and AKI following CAR-T cell infusion.
View article: Data from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Data from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
A common complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents with encephalopathy, aphasia, inattention, somnolence, seizures, weakness, or cerebra…